HAVCR2 and neoplasm: In addition to the expression of CTLA-4 and PDCD1, tumor-infiltrating lymphocytes (TILs) express a number of other co-inhibitory receptors, including HAVCR2 and TIGIT (68, 69), providing additional targets that could be exploited for inducing anti-tumor immune responses.